Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis - Scorecard - MDSpire
Advertisement
Investigation into the efficacy and safety profile of oral small-molecule GLP-1 receptor agonists in type 2 diabetes and obesity: a systematic review and meta-analysis
Clinical Scorecard: Assessment of the Effectiveness and Safety of Oral Small-Molecule GLP-1 Receptor Agonists for Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Type 2 Diabetes and Obesity
Key Mechanisms
Oral small-molecule GLP-1 receptor agonists improve glycemic control and promote weight reduction.
Target Population
Adults with Type 2 Diabetes or Obesity
Care Setting
Clinical trials evaluating efficacy and safety of oral GLP-1RAs
Key Highlights
Significant reduction in body weight (MD=-3.93 kg) and HbA1c (MD=-0.94%)
Increased likelihood of achieving ≥5%, ≥10%, and ≥15% body weight loss
Common adverse events include gastrointestinal issues such as nausea and vomiting
Serious adverse events were not significantly increased
Oral small-molecule GLP-1RAs may offer simpler administration compared to injectable options
Guideline-Based Recommendations
Diagnosis
Assess for Type 2 Diabetes and obesity in adults.
Management
Consider oral small-molecule GLP-1RAs for weight reduction and glycemic control.
Monitoring & Follow-up
Monitor for gastrointestinal adverse events during treatment.
Risks
Be aware of increased incidence of treatment-emergent adverse events.
Patient & Prescribing Data
Adults with Type 2 Diabetes or Obesity
Oral small-molecule GLP-1RAs provide significant metabolic benefits but require careful monitoring of adverse events.
Clinical Best Practices
Balance metabolic benefits against the risk of gastrointestinal adverse events.
Educate patients on potential side effects to improve adherence.
